{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:02:29Z","timestamp":1791093749054,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ejca.2013.11.005","type":"journal-article","created":{"date-parts":[[2013,11,29]],"date-time":"2013-11-29T14:30:18Z","timestamp":1385735418000},"page":"722-730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: The first step before intraperitoneal anti-vascular endothelial growth factor treatment?"],"prefix":"10.1016","volume":"50","author":[{"given":"G.","family":"Passot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bakrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vaudoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.N.","family":"Gilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2013.11.005_b0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejca.2013.11.005_b0010","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","article-title":"Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization","volume":"153","author":"Mesiano","year":"1998","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2013.11.005_b0015","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1245\/s10434-007-9699-7","article-title":"VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon","volume":"15","author":"Logan-Collins","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2013.11.005_b0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijgo.2009.11.021","article-title":"Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer","volume":"109","author":"Diniz Bizzo","year":"2010","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10.1016\/j.ejca.2013.11.005_b0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PPO.0b013e3181a58d67","article-title":"Management of peritoneal carcinomatosis from colorectal cancer: current state of practice","volume":"15","author":"Cotte","year":"2009","journal-title":"Cancer J"},{"issue":"6","key":"10.1016\/j.ejca.2013.11.005_b0030","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ejso.2006.03.009","article-title":"Systemic chemotherapy in the management of malignant peritoneal mesothelioma","volume":"32","author":"Garcia-Carbonero","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2013.11.005_b0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1525-1438.2003.13357.x","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel\u2013cisplatin regimen over the cyclophosphamide\u2013cisplatin combination in advanced ovarian cancer","volume":"13","author":"Piccart","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2013.11.005_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2013.11.005_b0045","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2013.11.005_b0050","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jso.21369","article-title":"Comparison of optimally resected hepatectomy and peritonectomy patients with colorectal cancer metastasis","volume":"100","author":"Cao","year":"2009","journal-title":"J Surg Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2013.11.005_b0055","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2007.12.1509","article-title":"Experience with bevacizumab in the management of epithelial ovarian cancer","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ejca.2013.11.005_b0060","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.ejca.2013.11.005_b0065","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2013.11.005_b0070","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1634\/theoncologist.2009-0109","article-title":"Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?","volume":"14","author":"Kobold","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2013.11.005_b0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"issue":"1","key":"10.1016\/j.ejca.2013.11.005_b0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejca.2013.11.005_b0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2013.11.005_b0090","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1634\/theoncologist.5-suppl_1-45","article-title":"Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation","volume":"5","author":"Verheul","year":"2000","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ejca.2013.11.005_b0095","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10637-009-9351-4","article-title":"Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review","volume":"28","author":"Bellati","year":"2010","journal-title":"Invest New Drugs"},{"issue":"18 Suppl.","key":"10.1016\/j.ejca.2013.11.005_b0100","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.1200\/jco.2007.25.18_suppl.9043","article-title":"Open label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites","volume":"25","author":"El-Shami","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2013.11.005_b0105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2008.04.028","article-title":"Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer","volume":"111","author":"Hamilton","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2013.11.005_b0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2013.11.005_b0115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-200868040-00009","article-title":"Bevacizumab: a review of its use in metastatic colorectal cancer","volume":"68","author":"McCormack","year":"2008","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejca.2013.11.005_b0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jso.20938","article-title":"\u201cSpontaneous\u201d, delayed colon and rectal anastomotic complications associated with bevacizumab therapy","volume":"97","author":"August","year":"2008","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2013.11.005_b0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jso.20301","article-title":"Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab","volume":"91","author":"Scappaticci","year":"2005","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2013.11.005_b0130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"Am J Hypertens"},{"issue":"12","key":"10.1016\/j.ejca.2013.11.005_b0135","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s12094-012-0888-x","article-title":"Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model","volume":"14","author":"Passot","year":"2012","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2013.11.005_b0140","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ejca.2013.11.005_b0145","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat Rep"},{"issue":"12","key":"10.1016\/j.ejca.2013.11.005_b0150","first-page":"3380","article-title":"Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy","volume":"49","author":"Los","year":"1989","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2013.11.005_b0155","first-page":"3209","article-title":"Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer","volume":"39","author":"Ozols","year":"1979","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2013.11.005_b0160","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/jpet.108.149443","article-title":"Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy","volume":"329","author":"Shah","year":"2009","journal-title":"Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.ejca.2013.11.005_b0165","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/annonc\/mdn540","article-title":"Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery","volume":"19","author":"Cacheux","year":"2008","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2013.11.005_b0170","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/annonc\/mdq566","article-title":"Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation","volume":"21","author":"Mautner","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2013.11.005_b0175","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/annonc\/mdt130","article-title":"A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer","volume":"24","author":"Powles","year":"2013","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2013.11.005_b0180","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1158\/1078-0432.CCR-09-3100","article-title":"Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy","volume":"16","author":"Bagri","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2013.11.005_b0185","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2013.11.005_b0190","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Hari, Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Ozcan","year":"2006","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2013.11.005_b0195","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ejca.2013.11.005_b0200","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.4161\/cbt.8.15.8943","article-title":"Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine","volume":"8","author":"Sun","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.ejca.2013.11.005_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000270179","article-title":"Bevacizumab for the treatment of non-resectable pseudomyxoma peritonei associated with mucinous ovarian tumor of low malignant potential \u2013 a comparison of two cases","volume":"3","author":"Winer","year":"2009","journal-title":"Case Rep Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2013.11.005_b0210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913010009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913010009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T01:59:52Z","timestamp":1597111192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913010009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0959804913010009"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.11.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: The first step before intraperitoneal anti-vascular endothelial growth factor treatment?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2013.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}